ArticleJournal of bone oncology2026
Incidence patterns and trends of chordoma in the United States: a population-based analysis of over 6,000 cases.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chordoma is a rare malignant bone tumor arising from notochordal remnants, with unknown etiology and limited descriptive characterization. Methods: Data from the North American Association of Central Cancer Registries, covering 93% of the U.S. population, were used to estimate age-standardized incidence rates and trends from 2003 to 2022 by demographic and clinical factors. Trends were quantified using Joinpoint regression. Data from 21 Surveillance, Epidemiology, and End Results (SEER) registries were used to estimate relative survival for cases diagnosed from 2003 to 2021. Results: A total of 6260 chordoma cases were diagnosed during 2003-2022. Cranial tumors were most frequent (38.7%), followed by sacral (32.7%) and spinal (25.4%) sites. The age-standardized incidence rate was 0.097 per 100,000, increasing with age and peaking at 80-84 years. Overall, incidence rates were higher in males than females (0.1173 versus 0.0800), with the divergence emerging after age 35. Incidence rates were comparable across racial and ethnic populations, except among non-Hispanic Black individuals, whose rates were 56% lower than those of non-Hispanic White individuals (95% CI = 0.39 to 0.49). Incidence rates were highest in the Northeast and metropolitan areas. From 2003 to 2022, incidence rose 1.47% annually (95% CI = 0.61-2.39), with steeper increases among younger individuals, women, and localized/cranial tumors. Among 2170 SEER cases, 5-year relative survival was 83.3%, varying by race/ethnicity and region. For distant-stage disease, survival ranged from 68.6% for cranial tumors to 38.3% for sacral tumors. Conclusion: Chordoma incidence and survival vary by demographic and clinical factors, suggesting differences in detection, healthcare access, and underlying etiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.